Effect of Noscapine and its derivative, EM101, on renal cell cancer and their mechanisms

诺斯卡平是临床可用的安全药物，在耐多药过表达的肿瘤中发现抗肿瘤作用。由于考虑到MDR过表达参与了肾癌的耐药过程，我们在肾癌细胞ACHN中加入诺斯平，并在体内体外证实了其抗肿瘤作用。我们证实了其在前列腺癌细胞系中的抗肿瘤作用。诺斯卡平不仅抑制雄激素非依赖性前列腺癌细胞DU145的增殖，而且抑制紫杉醇和多西紫杉醇耐药的DU145- txr的增殖。DU145-TxR过表达MDR mRNA和p-糖蛋白。为了研究诺斯卡平和黄酮类化合物在前列腺癌治疗中的协同作用，我们研究了黄酮类化合物对前列腺癌雄激素反应的影响。用PSA启动子驱动的荧光素酶报告基因转染LNCaP细胞后，用含黄酮的DHT处理细胞。柚皮素对雄激素反应有较强的抑制作用。

Noscapine is clinically available safe medicine, and antitumor action is found in MDR-overexpressing cancer. Because it was considered that MDR overexpression was involved in drug resistance of the renal carcinoma, we added Noscapine to renal carcinoma cells ACHN and confirmed antitumor effect in in vitro and in vivo. We confirmed antitumor effect in the prostate cancer cell line. Noscapine inhibited the proliferation of not only androgen-independent prostate caner cells DU145 but also DU145-TxR which is resistant for paclitaxel and docetaxel.DU145-TxR overexpressed MDR mRNA and p-glycoprotein that stimulate.For the purpose of expecting a synergistic effect with noscapine and flavonoids in prostate cancer, we investigated the effect of flavonoids on the androgen responsiveness. After LNCaP cells were transfected with PSA promoter-driven Luciferase reporter, cells were treated with DHT with flavonoids. Then naringenin showed the strong suppression of androgen responsiveness.